Arachidonyl trifluoromethyl ketone ameliorates experimental autoimmune encephalomyelitis via blocking peroxynitrite formation in mouse spinal cord white matter

Experimental Neurology

Volumn 231, Issue 1, 2011, Pages 45-55

  Vana, Adam C ^a   Li, Shihe ^a   Ribeiro, Rachel ^a   Tchantchou, Flaubert ^a   Zhang, Yumin ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Inducible nitric oxide synthase; Microglia; NADPH oxidase; Oligodendrocytes; Peroxynitrite; Phospholipase A2

Indexed keywords

3 NITROTYROSINE; ARACHIDONYL TRIFLUOROMETHYL KETONE; CYTOSOLIC PHOSPHOLIPASE A2; DOCEBENONE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; PROTEIN P47; PROTEIN P67; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; FEMALE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROGLIA; MONOTHERAPY; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD NERVE CELL; UPREGULATION; WEIGHT REDUCTION; WHITE MATTER;

ANIMALS; ANIMALS, NEWBORN; ARACHIDONIC ACIDS; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; OLIGODENDROGLIA; PEROXYNITROUS ACID; PHOSPHOLIPASES A2, CYTOSOLIC; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 79961025011     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.05.014     Document Type: Article

References (56)

1. Adibhatla R.M., Hatcher J.F. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 2008, 49:241-268.
2. Alvarez J.I., Cayrol R., Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:252-264.
3. Balsinde J., Balboa M.A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell. Signal. 2005, 17:1052-1062.
4. Baud O., Li J., Zhang Y., Neve R.L., Volpe J.J., Rosenberg P.A. Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur. J. Neurosci. 2004, 20:1713-1726.
5. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271:C1424-1437.
6. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345-350.
7. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206:165-171.
8. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
9. Bolton C., Gordon D., Turk J.L. Prostaglandin and thromboxane levels in central nervous system tissues from rats during the induction and development of experimental allergic encephalomyelitis (EAE). Immunopharmacology 1984, 7:101-107.
10. Bolton C., Scott G.S., Smith T., Flower R.J. The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinatoiron (III) chloride, (FeTPPS). Eur. J. Pharmacol. 2008, 601:88-93.
11. Cayrol R., Wosik K., Berard J.L., Dodelet-Devillers A., Ifergan I., Kebir H., Haqqani A.S., Kreymborg K., Krug S., Moumdjian R., Bouthillier A., Becher B., Arbour N., David S., Stanimirovic D., Prat A. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 2008, 9:137-145.
12. Chaudhary P., Marracci G.H., Bourdette D.N. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 175:87-96.
13. Cross A.H., San M., Stern M.K., Keeling R.M., Salvemini D., Misko T.P. A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 107:21-28.
14. Emerson M.R., LeVine S.M. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res. 2004, 1021:140-145.
15. Farooqui A.A., Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006, 12:245-260.
16. Farooqui A.A., Ong W.Y., Horrocks L.A. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 2006, 58:591-620.
17. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
18. Furlan R., Cuomo C., Martino G. Animal models of multiple sclerosis. Methods Mol. Biol. 2009, 549:157-173.
19. Ghomashchi F., Loo R., Balsinde J., Bartoli F., Apitz-Castro R., Clark J.D., Dennis E.A., Gelb M.H. Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A(2): structure-function studies with vesicle, micelle, and membrane assays. Biochim. Biophys. Acta 1999, 1420:45-56.
20. Hooper D.C., Bagasra O., Marini J.C., Zborek A., Ohnishi S.T., Kean R., Champion J.M., Sarker A.B., Bobroski L., Farber J.L., Akaike T., Maeda H., Koprowski H. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2528-2533.
21. Hooper D.C., Spitsin S., Kean R.B., Champion J.M., Dickson G.M., Chaudhry I., Koprowski H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:675-680.
22. Hooper D.C., Scott G.S., Zborek A., Mikheeva T., Kean R.B., Koprowski H., Spitsin S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 2000, 14:691-698.
23. James M.J., Cook-Johnson R.J., Cleland L.G. Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure. Lipids 2007, 42:779-785.
24. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
25. Kalyvas A., David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004, 41:323-335.
26. Kalyvas A., Baskakis C., Magrioti V., Constantinou-Kokotou V., Stephens D., Lopez-Vales R., Lu J.Q., Yong V.W., Dennis E.A., Kokotos G., David S. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 2009, 132:1221-1235.
27. Kihara Y., Ishii S., Kita Y., Toda A., Shimada A., Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J. Exp. Med. 2005, 202:853-863.
28. Kihara Y., Yanagida K., Masago K., Kita Y., Hishikawa D., Shindou H., Ishii S., Shimizu T. Platelet-activating factor production in the spinal cord of experimental allergic encephalomyelitis mice via the group IVA cytosolic phospholipase A2-lyso-PAFAT axis. J. Immunol. 2008, 181:5008-5014.
29. Kita Y., Ohto T., Uozumi N., Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim. Biophys. Acta 2006, 1761:1317-1322.
30. Kudo I., Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:3-58.
31. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp. Neurol. 2010, 225:2-8.
32. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9936-9941.
33. Liu J.S., Zhao M.L., Brosnan C.F., Lee S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 2001, 158:2057-2066.
34. Liu N.K., Zhang Y.P., Titsworth W.L., Jiang X., Han S., Lu P.H., Shields C.B., Xu X.M. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann. Neurol. 2006, 59:606-619.
35. Marusic S., Leach M.W., Pelker J.W., Azoitei M.L., Uozumi N., Cui J., Shen M.W., DeClercq C.M., Miyashiro J.S., Carito B.A., Thakker P., Simmons D.L., Leonard J.P., Shimizu T., Clark J.D. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 2005, 202:841-851.
36. Marusic S., Thakker P., Pelker J.W., Stedman N.L., Lee K.L., McKew J.C., Han L., Xu X., Wolf S.F., Borey A.J., Cui J., Shen M.W., Donahue F., Hassan-Zahraee M., Leach M.W., Shimizu T., Clark J.D. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 2008, 204:29-37.
37. Miyamoto K., Miyake S., Mizuno M., Oka N., Kusunoki S., Yamamura T. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006, 129:1984-1992.
38. Muthian G., Raikwar H.P., Johnson C., Rajasingh J., Kalgutkar A., Marnett L.J., Bright J.J. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J. Clin. Immunol. 2006, 26:73-85.
39. Ni J., Shu Y.Y., Zhu Y.N., Fu Y.F., Tang W., Zhong X.G., Wang H., Yang Y.F., Ren J., Wang M.W., Zuo J.P. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J. Neuroimmunol. 2007, 186:94-103.
40. Ospelt C., Kurowska-Stolarska M., Neidhart M., Michel B.A., Gay R.E., Laufer S., Gay S. The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands. Ann. Rheum. Dis. 2008, 67:524-529.
41. Prosiegel M., Neu I., Mallinger J., Wildfeuer A., Mehlber L., Vogl S., Hoffmann G., Ruhenstroth-Bauer G. Suppression of experimental autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition. Acta Neurol. Scand. 1989, 79:223-226.
42. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
43. Reder A.T., Thapar M., Sapugay A.M., Jensen M.A. Eicosenoids modify experimental allergic encephalomyelitis. Am. J. Ther. 1995, 2:711-720.
44. Sanchez-Mejia R.O., Newman J.W., Toh S., Yu G.Q., Zhou Y., Halabisky B., Cisse M., Scearce-Levie K., Cheng I.H., Gan L., Palop J.J., Bonventre J.V., Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 2008, 11:1311-1318.
45. Shelat P.B., Chalimoniuk M., Wang J.H., Strosznajder J.B., Lee J.C., Sun A.Y., Simonyi A., Sun G.Y. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J. Neurochem. 2008, 106:45-55.
46. Spitsin S., Hooper D.C., Leist T., Streletz L.J., Mikheeva T., Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult. Scler. 2001, 7:313-319.
47. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
48. Sun G.Y., Horrocks L.A., Farooqui A.A. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J. Neurochem. 2007, 103:1-16.
49. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
50. van Leyen K., Kim H.Y., Lee S.R., Jin G., Arai K., Lo E.H. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke 2006, 37:3014-3018.
51. Wang H., Li J., Follett P.L., Zhang Y., Cotanche D.A., Jensen F.E., Volpe J.J., Rosenberg P.A. 12-Lipoxygenase plays a key role in cell death caused by glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur. J. Neurosci. 2004, 20:2049-2058.
52. Wijewickrama G.T., Albanese A., Kim Y.J., Oh Y.S., Murray P.S., Takayanagi R., Tobe T., Masuda S., Murakami M., Kudo I., Ucker D.S., Murray D., Cho W. Unique membrane interaction mode of group IIF phospholipase A2. J. Biol. Chem. 2006, 281:32741-32754.
53. Wijewickrama G.T., Kim J.H., Kim Y.J., Abraham A., Oh Y., Ananthanarayanan B., Kwatia M., Ackerman S.J., Cho W. Systematic evaluation of transcellular activities of secretory phospholipases A2. High activity of group V phospholipases A2 to induce eicosanoid biosynthesis in neighboring inflammatory cells. J. Biol. Chem. 2006, 281:10935-10944.
54. Xie Z., Wei M., Morgan T.E., Fabrizio P., Han D., Finch C.E., Longo V.D. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J. Neurosci. 2002, 22:3484-3492.
55. Zhang Y., Wang H., Li J., Jimenez D.A., Levitan E.S., Aizenman E., Rosenberg P.A. Peroxynitrite-induced neuronal apoptosis is mediated by intracellular zinc release and 12-lipoxygenase activation. J. Neurosci. 2004, 24:10616-10627.
56. Zhang Y., Wang H., Li J., Dong L., Xu P., Chen W., Neve R.L., Volpe J.J., Rosenberg P.A. Intracellular zinc release and ERK phosphorylation are required upstream of 12-lipoxygenase activation in peroxynitrite toxicity to mature rat oligodendrocytes. J. Biol. Chem. 2006, 281:9460-9470.